JNJean Claude Semuto Ngabonziza

Jean Claude Semuto Ngabonziza

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jean Claude Semuto Ngabonziza has a total of 373 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Digitally Integrated Disease Management System in Rwanda: Community Healthcare Worker Perspectives

    by Jean Claude Semuto Ngabonziza, Nouh Saad Mohamed, Marie Fidele Muremba, Hervé Rutebuka, Sylvere Mugumya, Manasseh Wandera Gihana, Ayman Ahmed

    : As digital health tools are increasingly deployed to support community-based primary healthcare, understanding frontline user experiences is critical for effective implementation and scale-up. Here, community health workers’ (CHWs) perspectives on the digitally integrated disease management system (d-IDS) in Rwanda are discussed. The d-IDS intervention was intended to improve the cost-effectiveness of community-based screening, patient management, and disease surveillance through a mobile digital platform. Before implementation, user acceptance testing and cascade training prepared CHWs, their supervisors, and health facility staff. During implementation, continuous supervision and qualitative assessments of the system were conducted. Qualitative data were collected through focus group discussions and semi-structured key informant interviews. The CHWs widely appreciated the system’s ease of use, comprehensiveness, availability in Kinyarwanda (local language), offline functionality, improved data management, and ability to expedite effective patient management cascades compared with paper-based registers. Home-based screening reduced patient time and costs of care and enhanced equity and access to care, bringing Rwanda closer to achieving Universal Healthcare Coverage. However, challenges included increased workload, inadequate or lack of incentives, internet connectivity constraints, system rigidity in updating household records, and initially low digital literacy among some CHWs. Ongoing digitalization initiatives will inform national scale-up and policy choices.

  • Open Access

    Global patterns of genetic diversity and evolution in chikungunya virus E2 glycoprotein

    by Nouh Saad Mohamed, Jean Claude Semuto Ngabonziza, Ayman Ahmed

  • Open Access

    Marburg virus persistence and clinical complications among recovered persons in Rwanda: a longitudinal study protocol

    by Jcs Ngabonziza, Eric Seruyange, Nouh Saad Mohamed, Polina Brangel, Albert Tuyishime, Mary J Choi, Christine Dahlke, Eric Remera, James Kagame, Marrigje J Kreuger, et al.

    Introduction: Marburg virus (MARV) causes a potentially highly lethal haemorrhagic fever disease that threatens global health security, and knowledge of viral persistence, long-term clinical outcomes among recovered persons and protective immunity remain limited. Existing protocols and technical guidelines provide a framework for safe sample collection, clinical monitoring and outbreak response, yet systematic approaches to investigate these aspects in African settings are scarce. This protocol describes the Partnership Research on MARV (PREMAV) following the 2024 outbreak in Rwanda. PREMAV is a longitudinal study that was initiated to investigate the persistence of MARV in body fluids of recovered persons, characterises associated clinical complications, identifies factors associated with viral persistence, classifies the protective immune response and discovers genomic variants during viral persistence. Methods and analysis: This is a protocol for a prospective cohort study that enrolled individuals who survived Marburg virus disease (MVD), individuals with natural antibodies for MARV, close contacts and low risk controls in Rwanda. Participants will undergo serial sampling of blood, urine, semen and other relevant specimens over 24 months post-recovery. This will be combined with continuous clinical assessments, and laboratory analyses will include molecular detection, serological profiling, immunological assays and genomic viral characterisation. Statistical analysis will integrate the various datasets to determine associations. Ethics and dissemination: This study will adhere to the Declaration of Helsinki and obtain approval from the Rwanda National Ethics Committee. Written informed consent will be obtained from all participants with additional safeguards for vulnerable groups. Confidentiality will be ensured through de-identification and secure data storage. All biological samples will be handled in compliance with national and international biosafety standards. Psychosocial support will be provided to address stigma and mental health needs among survivors. The study will generate critical evidence on MARV persistence, clinical sequelae and risk factors, informing survivor care guidelines, transmission mitigation strategies and future outbreak preparedness. Findings will be disseminated through peer-reviewed publications, conferences and policy briefs targeting national and global stakeholders. De-identified data and genomic sequences will be curated and shared through secure platforms and public repositories in line with ethical and regulatory requirements.

  • Open Access

    Spatial clustering and transmission networks of multidrug-resistant tuberculosis in Rwanda: a national retrospective genomic and spatial epidemiological study

    by Isabel Cuella-Martin, Francois Hakizayezu, Wim Mulders, Hosee Niyompano, Docteur Runyambo, Jelle Keysers, Willem B De Rijk, Yves Habimana Mucyo, Patrick Migambi, Claude Mambo Muvunyi, et al.

    Background: Approximately 96% of rifampicin resistance/multidrug-resistant tuberculosis (RR/MDR-TB) cases in Rwanda result from direct transmission rather than acquired resistance. However, the nationwide spatial distribution and transmission dynamics of RR/MDR-TB remain poorly characterised. This study aims to analyse spatial patterns of RR/MDR-TB in Rwanda and explore relationships between spatial proximity and RR/MDR-TB strains’ genetic relatedness. Methods: We conducted a retrospective analysis of 249 confirmed RR-TB cases across Rwanda from 2017 to 2024, using the known geolocations of patients’ residences. Spatial and space-time clustering was assessed using Kulldorff’s scan statistics. Demographic and socioeconomic determinants were evaluated using multivariable regression. For 201 cases with whole-genome sequencing data, we performed transmission analysis using a 5-SNP threshold to define recent transmission clusters and investigated spatial relationships within genetically related strains. Results: Significant spatial clustering of RR/MDR-TB was identified in 21 sectors, mainly in Nyarugenge, southern Gasabo and western Kicukiro (relative risk: 10.06; p<0.001). Our multivariable analysis showed that population density is positively associated with case notification rates. Molecular analysis revealed 88.5% of cases belonged to genotype clusters defined using a 12-SNP threshold, with 73.6% forming clusters at a strict 5-SNP threshold. Spatial K-function analysis of the six major clusters revealed heterogeneous transmission patterns, characterised by both tightly clustered outbreaks and regional transmission networks that spanned administrative boundaries. Most clusters (5/6) extended beyond Kigali, indicating that transmission networks operate across administrative divides. Conclusion: RR/MDR-TB in Rwanda shows significant spatial clustering with transmission occurring through both localised and regional networks. Integrating genomic and spatial data reveals transmission patterns that extend beyond household contacts and administrative boundaries. These findings underscore the need to implement geographically targeted interventions that address community-level transmission to control RR/MDR-TB in Rwanda effectively.

  • Open Access

    Key operational challenges at a programmatic level to achieve optimal use of the GeneXpert platform

    by I. Cuella-Martin, F. Hakizayezu, E. Kamanzi, Y.M. Habimana, P. Migambi, B.C. de Jong, L. Rigouts, J.C.S. Ngabonziza

    SUMMARY: BACKGROUND: Although Xpert MTB/RIF Ultra (Ultra) has revolutionised TB diagnosis, operational challenges can significantly undermine its benefits. This study examined operational experiences and challenges associated with Ultra use across Rwanda’s health care settings. METHODS: We conducted a cross-sectional survey across 53 GeneXpert testing centres between October and December 2024. The survey addressed machine usage, sample processing timelines, and technical challenges through structured interviews with laboratory managers and operators. RESULTS: While 41% of sites processed samples within 5 h, 55% experienced delays exceeding 24 h due to high volumes and limited capacity. Four labs (8%) reported significant delays (>8 h) processing sputum with sample reagent. Modules failures occurred in 81% of facilities within the preceding year, with most experiencing infrequent failures and one site experiencing more than six annually. Connectivity issues with internet and/or ‘DataToCare’ affected 17% of sites, causing workflow delays. Equipment capacity constraints were identified in 30% of sites, particularly affecting facilities managing dual TB and HIV/hepatitis testing, while 9% reported staffing shortages. CONCLUSION: Despite successful nationwide deployment, operational challenges limit Ultra’s full potential. Strategic machine allocation, upgraded connectivity, and improved preventive maintenance represent key intervention areas. These findings offer valuable insights optimising rapid molecular diagnostic use in similar settings.

  • Open Access

    Tracking cross-border transmission of Rwanda’s successful dominant rifampicin-resistant Mycobacterium tuberculosis clone using genomic markers

    by Isabel Cuella-Martin, Wim Mulders, Jelle Keysers, Francois Hakizayezu, Hosee Niyompano, Docteur Runyambo, Willem Bram De Rijk, Jody Phelan, Yves Mucyo Habimana, Patrick Migambi, et al.

    Background: In Rwanda, genomic surveillance identified a dominant multidrug-resistant tuberculosis (MDR-TB) strain, the R3clone, responsible for approximately 70% of rifampicin-resistant TB cases. Its presence beyond Rwanda remains unexplored. Methods: Unique genetic signatures of the R3clone were defined using whole-genome sequencing of MDR-TB isolates from Rwanda. We developed a targeted qPCR assay detecting a clone-specific single-nucleotide polymorphism. With these tools, we screened isolates from neighbouring countries and public genomic repositories. Results: We identified 375 R3clone isolates, including 264 from historical Rwandan collections (1991-2021), 49 from recent Rwandan diagnostic routine (2021-2024), 25 from historical Burundi isolates (2002-2013), and 37 among public repositories from several countries. The R3clone-specific qPCR showed 100% specificity in distinguishing the R3clone from other MTBC (sub-)lineages. Transmission analysis revealed cross-border transmission of the R3clone within the Great Lakes Region. Conclusion: This study comprehensively assesses cross-border transmission of a dominant MDR-TB strain, highlighting the need for coordinated international surveillance. Impact statement: Tuberculosis management is primarily undertaken at a national level, with associated contact tracing and public health interventions also being performed within country. Several countries have signature strain or drug resistance patterns within their Mycobacterium tuberculosis population, allowing for tracking of circulating clones within their borders. Rwanda is one such case, with the R3clone dominating the MDR-TB cases within the country. Previous studies of the R3clone have shown that improved patient management and treatment can reduce the prevalence of this clone within Rwanda. Our study confirms this decline in population size of the R3clone within Rwanda. We also show that this is not a Rwanda-restricted clone; by developing a low-cost qPCR-based detection method we uncovered this clone in Burundi and through extended search of online databases additionally found it in other neighbouring countries. Our findings demonstrate that tracking of M. tuberculosis needs to extend beyond country borders, especially in endemic regions with high levels of inter-country migration. Cross-border tracking and co-operation will enhance intervention measures and reduce cases of MDR-TB transmission. Data summary: All samples sequenced in this project from the InnoR3Tb project (Rwanda and Burundi) are available via the ENA projects PRJEB106304 and PRJEB95959. The exact ENA accession codes for each sample are listed in Table S3 alongside sampling dates and countries.

  • Open Access

    Nucleoprotein and glycoprotein based serological assays for detection of Marburg virus infections

    by James Kagame, Markus H. Kainulainen, Emmanuel Kabalisa, Polina Brangel, Jean Marie Vianney Uwimana, Jessica R. Harmon, Nouh Saad Mohamed, Jean Luc Benimana, Ange Umwari, Elif Karaaslan, et al.


  • Open Access

    Remdesivir for Post-Exposure Prophylaxis of Marburg Virus Disease: A Retrospective Study Assessing Safety, Clinical, and Immunologic Outcome

    by Tsion Firew, Menelas Nkeshimana, Espoir Hakizimana, Michel R. Gatera, Kristine L. Keller, Anna Dobbins, Jean Claude Ngabonziza, Edson Rwagasore, Olivier Nsekuye, Appolinaire Manirafasha, et al.

    Background: Marburg Virus Disease (MVD) outbreaks have mortality rates up to 90% and disproportionately affect healthcare workers (HCWs). No approved treatments or prophylactic agents exist, but remdesivir has demonstrated protection in animal models. We conducted a retrospective cohort study to evaluate the safety, feasibility, and selected clinical and laboratory outcomes of remdesivir as post-exposure prophylaxis (PEP) during the 2024 MVD outbreak in Rwanda.Methods: Between September 27 and October 30, 2024, intravenous remdesivir (200 mg on Day 1 and 100 mg on Days 2–3) was offered as PEP to HCWs in MVD-affected units and family members of confirmed cases. Participants enrolled voluntarily with informed consent. Liver function tests, MVD infection status, seroprevalence, and symptom assessments were performed before and after infusion. Incubation periods and cycle threshold (Ct) values were compared between PCR-confirmed MVD cases who received PEP and those who did not.Findings: Of 380 participants, 194 (51%) received PEP and 186 (49%) did not. Overall, 12 participants (3.2%) developed PCR-confirmed MVD. The median incubation period was longer among PEP recipients than non-recipients (11 vs 8 days; p=0.0014). Seroprevalence was higher in the non-PEP group (1.61%) than in the PEP group (0.51%). Ct values were similar between groups, and no clinically significant changes in liver function tests were observed.Interpretation: Remdesivir appears safe and feasible for use as post-exposure prophylaxis during MVD outbreaks. Randomised controlled trials are required to determine preventive efficacy.

  • Open Access

    Effectiveness of a digital clinical decision support algorithm for guiding antibiotic prescribing in pediatric outpatient care in Rwanda: A pragmatic cluster non-randomized controlled trial

    by Alexandra V. Kulinkina, Victor P. Rwandarwacu, Joseph Habakurama, Ludovico Cobuccio, Martin Norris, Emmanuel Kalisa, Cassien Havugimana, Angelique Ingabire, Gillian A. Levine, Rainer Tan, et al.

    Background: Poor adherence to clinical guidelines and diagnostic uncertainty are key contributors to antibiotic overprescription, accelerating antimicrobial resistance. We developed ePOCT+, a digital clinical decision support algorithm (previously published) that integrated oxygen saturation, hemoglobin measurements, and C-reactive protein testing to assist primary care clinicians in managing acutely ill children aged 14 years or below. The goal was to reduce antibiotic prescriptions without compromising clinical recovery. Methods and findings: We conducted a pragmatic, open-label cluster non-randomized controlled trial in 32 Rwandan health centers allocated to two groups by geography, balancing patient volume and infrastructure. Sixteen sites used ePOCT+ throughout; the other 16 provided standard care for five months before crossing over. This design supported three comparisons: intervention–control (months 1–5), before–after (control sites pre- versus post-crossover), and longitudinal assessment (intervention sites over 10 months). ePOCT+ was deployed in a digital application; the same application (without the algorithm) served as an electronic case report form in the control arm. Outcomes were analyzed using mixed-effects logistic regression, adjusted for age, sex, district, and presenting complaints. Superiority in antibiotic prescription (primary outcome) was defined as ≥25% reduction versus routine care. Non-inferiority for clinical failure (main secondary outcome) was defined as adjusted risk ratio upper 95% CI <1.3. Several other secondary outcomes were analyzed and reported. Between December 2021 and April 2023, 59,921 consultations were enrolled and 47,822 new consultations were analyzed. ePOCT+ uptake averaged 70% across all intervention periods. In the primary per-protocol analysis, antibiotic prescriptions declined from 70.5% to 24.5% in the intervention–control comparison (absolute difference −46.0, 95% CI [−52.5, −39.5]) and to 27.5% in the before–after comparison (absolute difference −43.0, 95% CI [−49.7, −36.4]). Reductions in the intention-to-treat sensitivity analysis were −36.7 (95% CI [−42.1, −31.3]) in the intervention–control comparison and −26.7 (95% CI [−32.2, −21.4]) in the before–after comparison, respectively. Prescription rates remained low (25%–40%) throughout the longitudinal assessment. Clinical failure rates were non-inferior (per-protocol aRR 1.07, 95% CI [0.97, 1.18] and 1.00, 95% CI [0.92, 1.10] in intervention–control and before–after analyses, respectively). In the intervention–control comparison, referral rates (aRR 2.11, 95% CI [1.20, 3.70]), primary hospitalizations (aRR 2.02, 95% CI [1.21, 3.38]), secondary hospitalizations (aRR 1.93, 95% CI [1.17, 3.16]), and severe outcomes (comprised primarily of non-referred secondary hospitalizations; aRR 1.88, 95% CI [1.11, 3.15]) were higher in the intervention arm; no differences were observed in the before–after comparison, suggesting possible baseline differences in patient severity rather than intervention effects. Re-attendance rates did not differ between arms. Malaria testing among febrile cases improved (aRR 1.27, 95% CI [1.08, 1.41]), while treatment adherence remained high. Study limitations included non-randomized design and self-reported outcomes. Conclusions: ePOCT+ substantially reduced antibiotic prescribing in Rwandan pediatric primary care without compromising clinical recovery. Integration into Rwanda’s national electronic medical record platform is critical to ensure unified clinical and reporting functions. This could streamline service delivery, improve data quality, and promote evidence-based care at scale. Trial registration: Clinicaltrials.gov NCT 05108831


  • Top Cited Papers
    Open Access

    Implementation and evaluation of a community health workers-led digital integrated diseases screening system to provide healthcare for patients at community level in Rwanda

    by Jean Claude Semuto Ngabonziza, Khairunisa Suleiman, Nouh Saad Mohamed, Gilbert Rukundo, Marie Fidele Muremba, James Kagame, Jean Claude Mugisha, Hervé Rutebuka, Eric Remera, Emmanuel Edwar Siddig, et al.